School of Nursing, Jilin University, Changchun, Jilin, China.
Department of Anesthesiology, The Second Hospital of Jilin University, Changchun, Jilin, China.
PLoS One. 2023 Oct 10;18(10):e0292021. doi: 10.1371/journal.pone.0292021. eCollection 2023.
Although studies have shown severe Coronavirus disease 2019 (COVID-19) outcomes in patients with pre-existing coronary heart disease (CHD), the prognosis of COVID-19 patients with pre-existing CHD remains uncertain primarily due to the limited number of patients in existing studies. This study aimed to investigate the impacts of pre-existing CHD on the prognosis of COVID-19 patients. Five electronic databases were searched for eligible studies. This article focused on cohort and case-control studies involving the prognosis of COVID-19 patients with pre-existing CHD. The meta-analysis was performed using a random effects model. The odds ratios (ORs) and 95% confidence intervals (CIs) were used as valid indicators. The study was registered in PROSPERO with the identifier: CRD42022352853. A total of 81 studies, involving 157,439 COVID-19 patients, were included. The results showed that COVID-19 patients with pre-existing CHD exhibited an elevated risk of mortality (OR = 2.45; 95%CI: [2.04, 2.94], P < 0.001), severe/critical COVID-19 (OR = 2.57; 95%CI: [1.98, 3.33], P < 0.001), Intensive Care Unit or Coronary Care Unit (ICU/CCU) admission: (OR = 2.75, 95%CI: [1.61, 4.72], P = 0.002), and reduced odds of discharge/recovery (OR = 0.43, 95%CI: [0.28, 0.66], P < 0.001) compared to COVID-19 patients without pre-existing CHD. Subgroup analyses indicated that the prognosis of COVID-19 patients with pre-existing CHD was influenced by publication year, follow-up duration, gender, and hypertension. In conclusion, pre-existing CHD significantly increases the risk of poor prognosis in patients with COVID-19, particularly in those male or hypertensive patients.
虽然研究表明患有预先存在的冠心病 (CHD) 的 2019 年冠状病毒病 (COVID-19) 患者有严重后果,但由于现有研究中患者数量有限,COVID-19 患者合并预先存在的 CHD 的预后仍不确定。本研究旨在探讨预先存在的 CHD 对 COVID-19 患者预后的影响。检索了五个电子数据库以寻找符合条件的研究。本文重点关注涉及 COVID-19 患者合并预先存在的 CHD 预后的队列研究和病例对照研究。使用随机效应模型进行荟萃分析。使用优势比 (OR) 和 95%置信区间 (CI) 作为有效指标。本研究已在 PROSPERO 中注册,标识符为:CRD42022352853。共纳入 81 项研究,涉及 157439 例 COVID-19 患者。结果表明,患有预先存在的 CHD 的 COVID-19 患者的死亡率(OR = 2.45;95%CI:[2.04, 2.94],P < 0.001)、严重/危重症 COVID-19(OR = 2.57;95%CI:[1.98, 3.33],P < 0.001)、入住重症监护病房或冠心病监护病房(ICU/CCU)(OR = 2.75,95%CI:[1.61, 4.72],P = 0.002)和降低的出院/恢复几率(OR = 0.43,95%CI:[0.28, 0.66],P < 0.001)均高于无预先存在的 CHD 的 COVID-19 患者。亚组分析表明,预先存在的 CHD 对 COVID-19 患者的预后的影响取决于发表年份、随访时间、性别和高血压。总之,预先存在的 CHD 显著增加了 COVID-19 患者不良预后的风险,尤其是男性或高血压患者。